The Health Resources and Services Administration (HRSA) is forecasting a grant opportunity titled "Hereditary Hemorrhagic Telangiectasia (HHT) Center," aimed at reducing morbidity and mortality associated with HHT. The program's objectives include expanding access to care for HHT patients and developing a de-identified patient data registry to enhance understanding of this rare disease and its treatment outcomes. This cooperative agreement is crucial for improving health outcomes in affected populations, with an estimated total program funding of $2,000,000 and one expected award. Interested applicants, including domestic public or private entities and faith-based organizations, can reach out to Nordia Williams at (240) 475-3310 or via email at Nwilliams1@hrsa.gov for further details. The synopsis is expected to be posted on January 10, 2025, with a closing date of April 11, 2025, and the project is anticipated to start on September 30, 2025.